MedTrace Logo

Evaluation of the Effectiveness of a Protocol for the Management of Female Functional Urinary Signs

NCT05510128 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-03-13

No results posted yet for this study

Summary

Every year, between 4 and 6 million French people are affected by a urinary infection; the vast majority of these are women. Although the diagnosis of an uncomplicated urinary tract infection is simple to make, it requires prompt medical management to relieve the symptoms. The lack of immediate of a physician can slow down the management of patients affected by this condition, and lead to an inappropriate referral of patients to the emergency services.

Because of their wide availability, accessibility, and geographical distribution throughout the country, pharmacists are primary health care professionals who are regularly called upon to respond to patients with this type of infection.

A national protocol exists in France, but it is very difficult to apply. The PharmaCyst' study aims to evaluate its application in community pharmacies.

Conditions

  • Cystitis Acute

Interventions

OTHER

Pharmacist management

When a patient comes to the pharmacy with signs of urinary burning, the following will follow: * Completion of the acute cystitis symptoms score (ACSS) questionnaire. * Measure the temperature. * Perform a urine dipstick. If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made.

Sponsors & Collaborators

  • University Hospital, Angers

    lead OTHER_GOV

Principal Investigators

  • Sébastien Faure, Professor · University of Angers

  • Aline Ramond-Roquin, Professor · University of Angers

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-10-29
Completion
2025-01-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05510128 on ClinicalTrials.gov